source
- American Cancer Society recommends routine PSA screening for men 50-69, strengthens guidance for high-risk groupsThe American Cancer Society (ACS) has updated its prostate-cancer screening guidelines, now advising men at average risk aged 50 to 69 to have a PSA blood test every two years. This replaces the 20…
- Alnylam faces slowdown in Amvuttra sales, putting its growth ambitions at riskAlnylam’s market narrative has long hinged on the performance of its cardiomyopathy drug Amvuttra. The company once hoped the therapy could lift its valuation toward the $100 billion range. Recent…